626 related articles for article (PubMed ID: 34933307)
1. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
[TBL] [Abstract][Full Text] [Related]
4. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
5. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
Sanz Gómez I; Huguet J; Bravo A; Robalino J; Rodríguez Faba Ó; Territo Á; Gaya JM; Palou J; Breda A
Clin Genitourin Cancer; 2023 Aug; 21(4):e286-e290. PubMed ID: 37076337
[TBL] [Abstract][Full Text] [Related]
6. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
9. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
Busetto GM; Finati M; Chirico M; Cinelli F; D'Altilia N; Falagario UG; Sanguedolce F; Del Giudice F; De Berardinis E; Ferro M; Crocetto F; Porreca A; Di Gianfrancesco L; Calo' B; Mancini V; Bettocchi C; Carrieri G; Cormio L
World J Urol; 2023 May; 41(5):1329-1335. PubMed ID: 36971825
[TBL] [Abstract][Full Text] [Related]
11. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
Balasubramanian A; Gunjur A; Weickhardt A; Papa N; Bolton D; Lawrentschuk N; Perera M
World J Urol; 2022 May; 40(5):1111-1124. PubMed ID: 35083522
[TBL] [Abstract][Full Text] [Related]
13. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F
Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493
[TBL] [Abstract][Full Text] [Related]
15. Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
You C; Li Q; Qing L; Li R; Wang Y; Cheng L; Dong Z
Int Urol Nephrol; 2024 Jan; 56(1):103-120. PubMed ID: 37659995
[TBL] [Abstract][Full Text] [Related]
16. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
17. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
20. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]